| US 7,482,137 B2 | ||
| Hybrid glycosylated products and their production and use | ||
| Peter Francis Leadlay, Cambridge (United Kingdom); James Staunton, Cambridge (United Kingdom); and Sabine Gaisser, Cambridge (United Kingdom) | ||
| Assigned to Biotica Technology Limited, Essex (United Kingdom) | ||
| Filed on Oct. 12, 2006, as Appl. No. 11/580,263. | ||
| Application 11/580263 is a continuation of application No. 10/257549, abandoned, previously published as PCT/GB01/01743, filed on Apr. 17, 2001. | ||
| Application 10/257549 is a continuation in part of application No. 09/694218, filed on Oct. 23, 2000, abandoned. | ||
| Claims priority of application No. 0009207.2 (GB), filed on Apr. 13, 2000. | ||
| Prior Publication US 2007/0092944 A1, Apr. 26, 2007 | ||
| Int. Cl. C12N 9/10 (2006.01); C12N 1/21 (2006.01); C07H 21/04 (2006.01); C12P 21/06 (2006.01) | ||
| U.S. Cl. 435—68.1 [435/75; 435/101; 435/193; 536/23.1] | 2 Claims |
| 1. A hybrid glycosylated product which comprises:
(a) at least one rhamnose or substituted rhamnose sugar linked to an erythronolide or an erythromycin either at the 3 position
or 5 position or at both the 3 and 5 positions of said erythronolide or erythromycin, wherein the hybrid glycosylation product
is other than 3-rhamnosyl-5-desosaminyl-erythronolide B, 3-rhamnosyl-6-deoxyerythromycin B, 3-rhamnosyl-erythronolide B, and
3-rhamnosyl-6-deoxyerythronolide B;
(b) at least one mycarose or substituted mycarose sugar linked to an erythronolide or an erythromycin either at the 5 position
or at both the 3 and 5 positions of said erythronolide or erythromycin;
(c) at least one mycaminose or substituted mycaminose sugar linked to an erythronolide or an erythromycin either at the 3
position or at both the 3 and 5 positions of said erythronolide or erythromycin;
or combinations of (a), (b) and (c) sugar substituents on an erythronolide or erythromycin.
|